Jolanta M Siller-Matula1, Simon Specht2, Jacek Kubica3, Dimitrios Alexopoulos4, Raffaele De Caterina5, Eva-Luise Hobl6, Bernd Jilma6, Günter Christ7, Irene M Lang2. 1. Department of Cardiology, Medical University of Vienna, Vienna, Austria. jolanta.siller-matula@meduniwien.ac.at. 2. Department of Cardiology, Medical University of Vienna, Vienna, Austria. 3. Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. 4. Department of Cardiology, Patras University Hospital, Patras, Greece. 5. Institute of Cardiology, "G. d'Annunzio" University - Chieti-Pescara, Chieti, Italy. 6. Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. 7. 5th Medical Department of Cardiology, Kaiser Franz Josef Hospital, Vienna, Austria.
Abstract
OBJECTIVE: The present study investigated whether the glycoprotein (GP)IIb/IIIa receptor blocker abciximab might be a successful bridging strategy to achieve adequate levels of platelet inhibition rapidly in cases where prasugrel is used in morphine-pretreated ST-elevation myocardial infarction (STEMI) patients. METHODS: In a prospective observational cohort study, 32 patients presenting with STEMI were given prasugrel at a loading dose of 60 mg. Patients were stratified into four groups, according to morphine and/or abciximab use. Adenosine diphosphate (ADP)-induced platelet aggregation was measured at four time points: at baseline, and at 2 h, 1 day and 2 days after prasugrel loading. RESULTS: Morphine use was associated with a three-fold higher level of ADP-induced platelet aggregation 2 h after prasugrel loading compared with no morphine/no abciximab (P = 0.019). However, when abciximab was infused in the catheterization laboratory, the effect of morphine on ADP-induced platelet aggregation disappeared (P = 0.884). This interaction was also seen in the presence of high on-treatment platelet reactivity (HTPR) at 2 h; while HTPR was seen in 88% of morphine users/no abciximab users, it was found in only 17-20% in the three other groups (P = 0.003). The effect of morphine disappeared by day 1 - 2. CONCLUSION: The infusion of the GPIIb/IIIa receptor blocker abciximab allows immediate and efficient platelet inhibition in STEMI patients concomitantly receiving the oral ADP receptor blocker prasugrel and morphine.
OBJECTIVE: The present study investigated whether the glycoprotein (GP)IIb/IIIa receptor blocker abciximab might be a successful bridging strategy to achieve adequate levels of platelet inhibition rapidly in cases where prasugrel is used in morphine-pretreated ST-elevation myocardial infarction (STEMI) patients. METHODS: In a prospective observational cohort study, 32 patients presenting with STEMI were given prasugrel at a loading dose of 60 mg. Patients were stratified into four groups, according to morphine and/or abciximab use. Adenosine diphosphate (ADP)-induced platelet aggregation was measured at four time points: at baseline, and at 2 h, 1 day and 2 days after prasugrel loading. RESULTS:Morphine use was associated with a three-fold higher level of ADP-induced platelet aggregation 2 h after prasugrel loading compared with no morphine/no abciximab (P = 0.019). However, when abciximab was infused in the catheterization laboratory, the effect of morphine on ADP-induced platelet aggregation disappeared (P = 0.884). This interaction was also seen in the presence of high on-treatment platelet reactivity (HTPR) at 2 h; while HTPR was seen in 88% of morphine users/no abciximab users, it was found in only 17-20% in the three other groups (P = 0.003). The effect of morphine disappeared by day 1 - 2. CONCLUSION: The infusion of the GPIIb/IIIa receptor blocker abciximab allows immediate and efficient platelet inhibition in STEMI patients concomitantly receiving the oral ADP receptor blocker prasugrel and morphine.
Authors: Dániel Aradi; Ajay Kirtane; Laurent Bonello; Paul A Gurbel; Udaya S Tantry; Kurt Huber; Matthias K Freynhofer; Jurrien ten Berg; Paul Janssen; Dominick J Angiolillo; Jolanta M Siller-Matula; Rossella Marcucci; Giuseppe Patti; Fabio Mangiacapra; Marco Valgimigli; Olivier Morel; Tullio Palmerini; Matthew J Price; Thomas Cuisset; Adnan Kastrati; Gregg W Stone; Dirk Sibbing Journal: Eur Heart J Date: 2015-04-20 Impact factor: 29.983
Authors: Gilles Montalescot; Arnoud W van 't Hof; Frédéric Lapostolle; Johanne Silvain; Jens Flensted Lassen; Leonardo Bolognese; Warren J Cantor; Angel Cequier; Mohamed Chettibi; Shaun G Goodman; Christopher J Hammett; Kurt Huber; Magnus Janzon; Béla Merkely; Robert F Storey; Uwe Zeymer; Olivier Stibbe; Patrick Ecollan; Wim M J M Heutz; Eva Swahn; Jean-Philippe Collet; Frank F Willems; Caroline Baradat; Muriel Licour; Anne Tsatsaris; Eric Vicaut; Christian W Hamm Journal: N Engl J Med Date: 2014-09-01 Impact factor: 91.245
Authors: Francesco Franchi; Fabiana Rollini; Jung Rae Cho; Mona Bhatti; Christopher DeGroat; Elisabetta Ferrante; Elizabeth C Dunn; Amit Nanavati; Edward Carraway; Siva Suryadevara; Martin M Zenni; Luis A Guzman; Theodore A Bass; Dominick J Angiolillo Journal: JACC Cardiovasc Interv Date: 2015-09 Impact factor: 11.195
Authors: Jacek Kubica; Piotr Adamski; Małgorzata Ostrowska; Joanna Sikora; Julia Maria Kubica; Wiktor Dariusz Sroka; Katarzyna Stankowska; Katarzyna Buszko; Eliano Pio Navarese; Bernd Jilma; Jolanta Maria Siller-Matula; Michał Piotr Marszałł; Danuta Rość; Marek Koziński Journal: Eur Heart J Date: 2015-10-21 Impact factor: 29.983
Authors: Julia M Umińska; Jakub Ratajczak; Katarzyna Buszko; Przemysław Sobczak; Wiktor Sroka; Michał P Marszałł; Piotr Adamski; Klemen Steblovnik; Marko Noč; Jacek Kubica Journal: Cardiol J Date: 2019-02-25 Impact factor: 2.737
Authors: Wael Sumaya; William A E Parker; Rebekah Fretwell; Ian R Hall; David S Barmby; James D Richardson; Javaid Iqbal; Zulfiquar Adam; Kenneth P Morgan; Julian P Gunn; Annah E Mason; Heather M Judge; Christopher P Gale; Ramzi A Ajjan; Robert F Storey Journal: Thromb Haemost Date: 2018-06-06 Impact factor: 5.249
Authors: Małgorzata Ostrowska; Jacek Kubica; Piotr Adamski; Aldona Kubica; Ceren Eyileten; Marek Postula; Aurel Toma; Christian Hengstenberg; Jolanta M Siller-Matula Journal: Front Cardiovasc Med Date: 2019-12-03
Authors: Aldona Kubica; Agata Kosobucka; Piotr Niezgoda; Piotr Adamski; Katarzyna Buszko; Maciej Lesiak; Wojciech Wojakowski; Mariusz Gasior; Jarosław Gorący; Andrzej Kleinrok; Klaudiusz Nadolny; Eliano Navarese; Jacek Kubica Journal: BMJ Open Date: 2021-03-01 Impact factor: 2.692
Authors: K S Rathod; S Antoniou; P Avari; N Ding; P Wright; C Knight; A K Jain; A Mathur; E J Smith; R Weerackody; A Wragg; D A Jones Journal: JRSM Cardiovasc Dis Date: 2017-10-05
Authors: Piotr Adamski; Joanna Sikora; Ewa Laskowska; Katarzyna Buszko; Małgorzata Ostrowska; Julia M Umińska; Adam Sikora; Natalia Skibińska; Przemysław Sobczak; Urszula Adamska; Danuta Rość; Aldona Kubica; Przemysław Paciorek; Michał P Marszałł; Eliano P Navarese; Diana A Gorog; Jacek Kubica Journal: PLoS One Date: 2017-10-12 Impact factor: 3.240